Oncotype Dx 复发评分 (RS) 可预测和预测激素受体阳性 (HR )、人表皮生长因子受体 2 阴性 (HER2-) 早期乳腺癌淋巴结阴性和淋巴结阳性女性的化疗获益。然而，其直接成本可能会受到抑制。本研究评估了 RS 和免费在线 PREDICT 工具对辅助化疗获益的估计之间的相关性。对 112 名接受 RS 和 PREDICT 工具测试的肿瘤患者的电子病历进行了回顾性审查，用于估计生存获益。使用 Spearman 等级和 McNemar 检验分析 RS 和 PREDICT 估计值之间的相关性。患者的中位年龄为 53 岁（95% CI，50 至 55）岁，大多数患者腋窝淋巴结阴性（78%）。虽然 RS 的绝对值与 PREDICT 估计的辅助化疗获益呈显着正相关，但两种方法之间的化疗获益百分比没有发现显着相关性。值得注意的是，在研究人群和亚组中，基于 RS 的风险分配与基于 PREDICT 估计的风险分配之间的不一致率在 48% 和 67% 之间，差异显着。在中位随访 23.5 个月（95% CI，19.8 至 27.2）个月内，仅记录了 1 例疾病复发和 1 例乳腺癌相关死亡。我们的研究结果强调了 RS 和 PREDICT 工具在预测辅助化疗益处方面存在显着不一致HR、HER2-早期乳腺癌患者。虽然这两种工具都旨在个性化癌症治疗，但它们的不一致程度各不相同，这表明 PREDICT 不能替代 RS 来预测辅助化疗的益处，无论患者风险分类如何。需要进一步的研究来探索这些关系并优化乳腺癌管理中的精准医学方法。

Oncotype Dx Recurrence Score (RS) is prognostic and predictive of chemotherapy benefit in women with node-negative and node-positive in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer. Nevertheless, its direct cost may be inhibitive. This study assesses the correlation between the RS and the free online PREDICT tools' estimations of adjuvant chemotherapy benefit.A retrospective review of the electronic medical records of 112 patients with tumors tested for the RS and the PREDICT tool was used to estimate survival benefits. The correlation between RS and PREDICT estimations was analyzed using Spearman rank and McNemar tests.The median age of patients was 53 (95% CI, 50 to 55) years, with most patients having negative axillary lymph nodes (78%). While the absolute value for RS showed significant positive correlations with adjuvant chemotherapy's benefit as estimated by PREDICT, no significant correlations were found between the two methods in the percentage of chemotherapy gain. Notably, discordance rates between 48% and 67% between RS-based risk assignments and those based on PREDICT estimates were significant across the study population and subgroups. Only one disease recurrence and one breast cancer-related death were documented over a median follow-up of 23.5 (95% CI, 19.8 to 27.2) months.Our findings highlight a significant discordance between RS and PREDICT tools in predicting the benefits of adjuvant chemotherapy in patients with HR+, HER2- early breast cancer. While both tools aim to personalize cancer treatment, their discordance varies, suggesting that PREDICT could not substitute RS to predict adjuvant chemotherapy benefits regardless of patient risk classification. Further studies are needed to explore these relationships and optimize precision medicine approaches in breast cancer management.